

# CITATION REPORT

List of articles citing

## Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines

DOI: 10.1007/s11926-007-0075-1

Current Rheumatology Reports, 2007, 9, 461-7.

**Source:** <https://exaly.com/paper-pdf/43157029/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
310	Clinical trials report. <i>Current Rheumatology Reports</i> , <b>2007</b> , 9, 435-436	4.9	
309	Interleukine-23 : une cytokine clef dans les maladies inflammatoires chroniques. <b>2008</b> , 75, 773-775		
308	Physiopathologie de la spondylarthrite ankylosante. <i>Actualités</i> . <b>2008</b> , 75, 925-930		
307	T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. <b>2008</b> , 128, 1064-7		114
306	Interleukin 23: a key cytokine in chronic inflammatory disease. <b>2008</b> , 75, 517-9		19
305	Pathophysiology of ankylosing spondylitis: what's new?. <b>2008</b> , 75, 656-60		25
304	Ustekinumab for chronic plaque psoriasis. <b>2008</b> , 371, 1639-40		34
303	Chemotherapy for malignant pleural mesothelioma. <b>2008</b> , 371, 1640-2		21
302	Application of angiogenesis to clinical dermatology. <b>2008</b> , 24, 89-103		12
301	TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis. <b>2008</b> , 20, 1097-106		52
300	Th17 cells: a new therapeutic target in inflammatory dermatoses. <b>2008</b> , 19, 318-26		47
299	Th17 cells: a new paradigm for cutaneous inflammation. <b>2008</b> , 19, 259-66		31
298	Moderate-to-Severe Psoriasis. <b>2008</b> ,		
297	Cardiometabolic risk in psoriasis: differential effects of biologic agents. <b>2008</b> , 4, 1229-35		15
296	CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. <b>2009</b> , 119, 2317-29		174
295	Translational perspectives on psoriatic arthritis. <b>2009</b> , 83, 30-4		7
294	Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. <b>2009</b> , 60, 1647-56		412

293	Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients. <b>2009</b> , 28, 187-90	36
292	Angiogenesis drives psoriasis pathogenesis. <b>2009</b> , 90, 232-48	222
291	Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. <b>2009</b> , 160, 319-24	229
290	Psoriasis and streptococci: the natural selection of psoriasis revisited. <b>2009</b> , 160, 929-37	63
289	Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. <b>2009</b> , 161, 1081-8	115
288	Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. <b>2009</b> , 129, 827-33	47
287	Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. <b>2009</b> , 129, 2175-83	333
286	Inflammatory skin disease in K5.hTGF-beta1 transgenic mice is not dependent on the IL-23/Th17 inflammatory pathway. <b>2009</b> , 129, 2443-50	23
285	Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. <b>2009</b> , 129, 2451-62	52
284	Recent advances in T-cell regulation relevant to inflammatory dermatopathology. <b>2009</b> , 36, 721-8	3
283	Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-alpha and interferon-alpha. <b>2009</b> , 56, 163-7	9
282	Ustekinumab for psoriatic arthritis. <b>2009</b> , 373, 605-6	17
281	Diagnosis and Management of Psoriatic Arthritis. <b>2009</b> , 1, 283-293	1
280	Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. <b>2009</b> , 145, 379-82	171
279	Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells. <b>2009</b> , 2009, 116-117	
278	Polymorphisms of the IL12B and IL23R Genes Are Associated with Psoriasis. <b>2009</b> , 2009, 115-116	
277	Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. <b>2010</b> , 2, 52ra72	677
276	De nouvelles cibles cytokiniques dans la polyarthrite rhumatoïde : le tocilizumab et les autres inhibiteurs des cytokines. <b>2010</b> , 77, S32-S40	0

275	Psoriasis and the metabolic syndrome. <b>2010</b> , 23, 137-43	51
274	Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. <b>2010</b> , 160, 810-20	97
273	MAP17 is associated with the T-helper cell cytokine-induced down-regulation of filaggrin transcription in human keratinocytes. <b>2010</b> , 19, 355-62	37
272	Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor- $\alpha$ levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. <b>2010</b> , 163, 1282-90	100
271	Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNF $\alpha$ therapy. <b>2010</b> , 163, 1194-204	46
270	Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation model. <b>2010</b> , 130, 455-63	8
269	Absence of IL-23p19 in donor allogeneic cells reduces mortality from acute GVHD. <b>2010</b> , 45, 712-22	18
268	Possible roles of IL-27 in the pathogenesis of psoriasis. <b>2010</b> , 130, 1034-9	66
267	Challenging Cases in Allergic and Immunologic Diseases of the Skin. <b>2010</b> ,	
266	Evaluation of a range of anti-proliferative assays for the preclinical screening of anti-psoriatic drugs: a comparison of colorimetric and fluorimetric assays with the thymidine incorporation assay. <b>2010</b> , 8, 389-400	13
265	Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis. <b>2010</b> , 10, 161-7	18
264	Progress in epidermolysis bullosa research: toward treatment and cure. <b>2010</b> , 130, 1778-84	57
263	IL-23 antagonizes UVR-induced immunosuppression through two mechanisms: reduction of UVR-induced DNA damage and inhibition of UVR-induced regulatory T cells. <b>2010</b> , 130, 554-62	25
262	Psoriasis and its treatment with adalimumab. <b>2010</b> , 10, 133-52	4
261	Allergic skin diseases. <b>2010</b> , 125, S138-49	94
260	Neutrophil-dominant psoriasis-like skin inflammation induced by epidermal-specific expression of Raf in mice. <b>2010</b> , 58, 28-35	14
259	Erratum to "Neutrophil-dominant psoriasis-like skin inflammation induced by epidermal-specific expression of Raf in mice" [J. Dermatol. Sci. 58 (2010) 28-35]. <b>2010</b> , 59, 64-71	
258	Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. <b>2010</b> , 63, 1058-69	87

257	Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. <b>2010</b> , 49, 163-70	35
256	Announcing a New Online Feature. <b>2010</b> , 63, 1069	
255	Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus. <b>2010</b> , 12, R150	47
254	Psoriasis: targeting therapy towards the inflammatory cascade. <b>2010</b> , 11 Suppl 1, 11-3	5
253	Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. <b>2011</b> , 186, 4481-9	135
252	Connective Tissue Diseases and Psoriasis. <b>2011</b> , 102, 487-497	
251	[Connective tissue diseases and psoriasis]. <b>2011</b> , 102, 487-97	12
250	Cytokine profiles in localized scleroderma and relationship to clinical features. <b>2011</b> , 55, 157-64	71
249	Markedly elevated serum levels of calcium-binding S100A8/A9 proteins in psoriatic arthritis are due to activated monocytes/macrophages. <b>2011</b> , 64, 879-87	39
248	Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. <b>2011</b> , 5, 41-9	12
247	Psoriasis Treatments: A Review of the Current Research Pipeline. <b>2011</b> , 17a, 11-23	2
246	Immunity to Parasites. <b>2011</b> , 7, 25-43	2
245	Serum levels of interleukin-8, tumor necrosis factor- $\alpha$ and Interferon in Egyptian psoriatic patients and correlation with disease severity. <b>2011</b> , 38, 442-6	24
244	Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice. <b>2011</b> , 164, 750-8	48
243	Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. <b>2011</b> , 20, 845-7	63
242	Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases. <b>2011</b> , 68, 931-49	138
241	IL-33 induces skin inflammation with mast cell and neutrophil activation. <b>2011</b> , 41, 2229-37	112
240	Progress in the development of small molecule therapeutics targeting Th17 cell function for the treatment of immune-inflammatory diseases. <b>2011</b> , 50, 109-33	6

239	Cytokine network in psoriasis revisited. <b>2011</b> , 22, 160-8	64
238	IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms. <b>2011</b> , 131, 2401-8	93
237	Epidermal CCR6+ T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. <b>2011</b> , 187, 5026-31	118
236	Role of interleukin-23 (IL-23) receptor signaling for IL-17 responses in human Lyme disease. <b>2011</b> , 79, 4681-7	32
235	Psoriatic disease and tuberculosis nowadays. <b>2012</b> , 2012, 747204	12
234	Biochemical markers of psoriasis as a metabolic disease. <b>2012</b> , 50, 155-70	21
233	Increased serum levels of miR-1266 in patients with psoriasis vulgaris. <b>2012</b> , 22, 68-71	33
232	Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. <b>2012</b> , 167, 710-3; discussion 714-5	37
231	Psoriasis: Ustekinumab and Other Biologics in the Pipeline. <b>2012</b> , 1, 108-114	1
230	Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. <b>2012</b> , 366, 1190-9	751
229	Association of IL-12B genetic polymorphism with the susceptibility and disease severity of ankylosing spondylitis. <b>2012</b> , 39, 135-40	43
228	Leprosy and the natural selection for psoriasis. <b>2012</b> , 78, 183-90	15
227	Chemokine receptors in the pathogenesis and therapy of psoriasis. <b>2012</b> , 65, 4-11	64
226	T helper type 17 in psoriasis: From basic immunology to clinical practice. <b>2012</b> , 30, 136-141	40
225	Pathophysiology of chemokines and chemokine receptors in dermatological science: A focus on psoriasis and cutaneous T-cell lymphoma. <b>2012</b> , 30, 128-135	14
224	Functional role of IL-22 in psoriatic arthritis. <b>2012</b> , 14, R65	73
223	Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. <b>2012</b> , 7, e31000	145
222	Evaluation of the T helper 17 axis in ankylosing spondylitis. <b>2012</b> , 32, 2511-5	21

221	Psoriasis and metabolic syndrome. <b>2012</b> , 39, 212-8	80
220	Topical valrubicin application reduces skin inflammation in murine models. <b>2012</b> , 167, 288-95	4
219	Interleukin-23 as a potential therapeutic target for rheumatoid arthritis. <b>2012</b> , 361, 243-8	21
218	Exploring the role of prolactin in psoriasis. <b>2012</b> , 304, 115-8	15
217	Role of IL-17 in psoriasis and psoriatic arthritis. <b>2013</b> , 44, 183-93	123
216	Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF- $\alpha$ therapy. <b>2013</b> , 33, 151-61	92
215	Using EAE to better understand principles of immune function and autoimmune pathology. <b>2013</b> , 45, 31-9	160
214	Chemokine receptors in psoriasis. <b>2013</b> , 17, 1405-22	16
213	Gene-gene interactions in IL23/Th17 pathway contribute to psoriasis susceptibility in Chinese Han population. <b>2013</b> , 27, 1156-62	12
212	TGF $\beta$ /Smad signalling in psoriatic epidermis models exposed to salt water soaks and narrowband ultraviolet B radiation. <b>2013</b> , 64, 35-8	7
211	Kurarinone regulates immune responses through regulation of the JAK/STAT and TCR-mediated signaling pathways. <b>2013</b> , 85, 1134-44	36
210	Effects of the Janus kinase inhibitor CP-690550 (tofacitinib) in a rat model of oxazolone-induced chronic dermatitis. <b>2013</b> , 91, 207-13	22
209	Impaired nuclear translocation of glucocorticoid receptors: novel findings from psoriatic epidermal keratinocytes. <b>2013</b> , 70, 2205-20	23
208	IL-22 contributes to TGF $\beta$ -mediated epithelial-mesenchymal transition in asthmatic bronchial epithelial cells. <b>2013</b> , 14, 118	57
207	Treatment of psoriasis and psoriatic arthritis. <b>2013</b> , 27 Suppl 1, 3-12	39
206	CXCR4 negatively regulates keratinocyte proliferation in IL-23-mediated psoriasiform dermatitis. <b>2013</b> , 133, 2530-2537	15
205	CCR6 is required for epidermal trafficking of Th17 cells in an IL-23-induced model of psoriasiform dermatitis. <b>2013</b> , 133, 164-71	99
204	Barrier abnormality due to ceramide deficiency leads to psoriasiform inflammation in a mouse model. <b>2013</b> , 133, 2555-2565	41

203	Correlations between psoriasis and inflammatory bowel diseases. <b>2013</b> , 2013, 983902	61
202	Pathophysiology of psoriasis. <b>2013</b> , 79 Suppl 7, S1-9	20
201	Effect of narrow-band ultraviolet B on the level of interleukin-17 in psoriasis patients. <b>2013</b> , 10, 85-88	
200	Effect of Narrow Band Ultraviolet B Therapy versus Methotrexate on Serum Levels of Interleukin-17 and Interleukin-23 in Egyptian Patients with Severe Psoriasis. <b>2013</b> , 2013, 618269	11
199	Frequency and spectrum of myopathies in patients with psoriasis. <b>2013</b> , 48, 716-21	5
198	Interleukin-17/T-helper 17 cells in an atopic dermatitis mouse model aggravate orthodontic root resorption in dental pulp. <b>2013</b> , 121, 101-10	19
197	The IL23R A/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and impairs Th17 responses in psoriasis patients. <b>2013</b> , 133, 2381-2389	44
196	Role of serum IL-23/IL-17 axis in the relationship between periodontitis and coronary heart disease. <b>2013</b> , 33, 185-91	11
195	Aberrant T helper 17 cells and related cytokines in bone marrow microenvironment of patients with acute myeloid leukemia. <b>2013</b> , 2013, 915873	10
194	Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis. <b>2014</b> , 9, 89-97	18
193	Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. <b>2014</b> , 18, 156-69	66
192	Immunologic biomarkers for clinical and therapeutic management of psoriasis. <b>2014</b> , 2014, 236060	15
191	When anti-TNF fails, anti-IL12-23 is an alternate option in psoriasis and psoriatic arthritis. <b>2014</b> , 54, 247-249	
190	Posttranscriptional modulation of cytokine production in T cells for the regulation of excessive inflammation by TFL. <b>2014</b> , 192, 1512-24	33
189	Specific targeting of interleukin-23p19 as effective treatment for psoriasis. <b>2014</b> , 70, 555-61	54
188	Interleukin 17A: toward a new understanding of psoriasis pathogenesis. <b>2014</b> , 71, 141-50	206
187	Increased percentages of PD-1 on CD4+ T cells is associated with higher INF- $\gamma$ production and altered IL-17 production in patients with systemic lupus erythematosus. <b>2014</b> , 43, 307-13	23
186	Advances in Psoriasis. <b>2014</b> ,	3



185	IL23R and ATG16L1 variants in Moroccan patients with inflammatory bowel disease. <b>2014</b> , 7, 570	11
184	Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. <b>2014</b> , 46, 114-22	52
183	An innovative three-dimensional model of normal human skin to study the proinflammatory psoriatic effects of tumor necrosis factor-alpha and interleukin-17. <b>2014</b> , 68, 1-8	27
182	Counter-regulation of T cell effector function by differentially activated p38. <b>2014</b> , 211, 1257-70	26
181	Quando anti-TNF nã obtm sucesso, anti-IL-12-23 ãpã alternativa na psorãse e na artrite psoriãica. <b>2014</b> , 54, 247-249	4
180	New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. <b>2015</b> , 28, 179-93	46
179	Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. <b>2015</b> , 29, 1148-55	76
178	Cross Talk between Proliferative, Angiogenic, and Cellular Mechanisms Orchestrated by HIF-1ãn Psoriasis. <b>2015</b> , 2015, 607363	15
177	The role of IL-17 in psoriasis. <b>2015</b> , 26, 41-4	48
176	TNF inhibitors directly target Th17 cells via attenuation of autonomous TNF/TNFR2 signalling in psoriasis. <b>2015</b> , 77, 79-81	5
175	Fatigue in psoriasis: a phenomenon to be explored. <b>2015</b> , 172, 1196-203	22
174	Expression of T-helper 17 cells and signal transducers in patients with psoriasis vulgaris of blood-heat syndrome and blood-stasis syndrome. <b>2015</b> , 21, 10-6	9
173	Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin. <b>2015</b> , 80, 38-44	10
172	Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation. <b>2015</b> , 99, 248-57	67
171	History of Immunology Research. <b>2015</b> , 1-58	
170	Energy and Volume Regulation. <b>2015</b> , 131-149	
169	References. <b>2015</b> , 261-355	
168	Anti-TNF-ã monoclonal antibody reverses psoriasis through dual inhibition of inflammation and angiogenesis. <b>2015</b> , 28, 731-43	26

167	Circadian Gene Clock Regulates Psoriasis-Like Skin Inflammation in Mice. <b>2015</b> , 135, 3001-3008	39
166	An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. <b>2015</b> , 26, 25-33	125
165	Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). <b>2015</b> , 172, 484-93	230
164	Vitamin D and the skin: Focus on a complex relationship: A review. <b>2015</b> , 6, 793-804	89
163	Psoriatic inflammation facilitates the onset of arthritis in a mouse model. <b>2015</b> , 135, 445-453	33
162	Th17 Cells. <b>2016</b> , 133-163	1
161	Psoriasis and Inflammatory Bowel Diseases: Epidemiological, Genetic and Pathogenetic Correlations: A Review of Literature. <b>2016</b> , 07,	
160	Overexpression and potential roles of NRIP1 in psoriasis. <b>2016</b> , 7, 74236-74246	18
159	Psoriasis and inflammatory bowel disease: links and risks. <b>2016</b> , 6, 73-92	23
158	CD19+ B cell subsets in the peripheral blood and skin lesions of psoriasis patients and their correlations with disease severity. <b>2016</b> , 49, e5374	18
157	Elevation of serum squamous cell carcinoma antigen 2 in patients with psoriasis: associations with disease severity and response to the treatment. <b>2016</b> , 174, 1327-36	21
156	A possible pathogenetic role of IL-23/IL-17 axis in rheumatoid nodules in patients with rheumatoid arthritis. <b>2016</b> , 170, 20-1	7
155	Regulation of IL-17A expression in mice following subacute ozone exposure. <b>2016</b> , 13, 428-38	5
154	Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. <b>2016</b> , 174, 136-45	54
153	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. <b>2016</b> , 175, 273-86	297
152	Increased MicroRNA-1266 levels as a biomarker for disease activity in psoriasis vulgaris. <b>2016</b> , 55, 1242-1247	12
151	Interleukin-17 and interleukin-23 regulate Langerhans cell migration. <b>2016</b> , 175, 622-4	3
150	Mucocutaneous findings associated with interleukin (IL)-17 inhibition. <b>2016</b> , 2, 92-4	4

149	Olfactory functions in patients with psoriasis vulgaris: correlations with the severity of the disease. <b>2016</b> , 308, 409-14	9
148	Inhibition of imiquimod-induced psoriasis-like dermatitis in mice by herbal extracts from some Indian medicinal plants. <b>2016</b> , 253, 503-15	13
147	CX3CR1 deficiency attenuates imiquimod-induced psoriasis-like skin inflammation with decreased M1 macrophages. <b>2016</b> , 82, 175-88	29
146	Treating psoriasis by targeting its susceptibility gene Rel. <b>2016</b> , 165, 47-54	15
145	Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis. <b>2016</b> , 16, 255-63	17
144	Effect of narrow band ultraviolet B phototherapy on T helper 17 cell specific cytokines (interleukins-17, 22 and 23) in psoriasis vulgaris. <b>2017</b> , 28, 14-17	4
143	p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells. <b>2017</b> , 50, 102-113	19
142	Tildrakizumab for treating psoriasis. <b>2017</b> , 17, 645-657	10
141	Interleukin-17RA Promotes Humoral Responses and Glomerular Injury in Experimental Rapidly Progressive Glomerulonephritis. <b>2017</b> , 135, 207-223	8
140	A novel approach for construction of an inactivated typhoid vaccine candidate that effectively augments both humoral and cellular immune responses. <b>2017</b> , 35, 3333-3341	1
139	Withasteroid B from <i>D. metel</i> L. regulates immune responses by modulating the JAK/STAT pathway and the IL-17 ROR $\gamma$ /IL-10 FoxP3 ratio. <b>2017</b> , 190, 40-53	12
138	Digestive system in psoriasis: an update. <b>2017</b> , 309, 679-693	25
137	Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis. <b>2017</b> , 31, 1627-1632	22
136	Widespread psoriasis flare following influenza vaccination. <b>2017</b> , 35, 4785-4786	9
135	Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: A population-based cross-sectional study. <b>2017</b> , 76, 40-48	60
134	Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders. <b>2017</b> , 22,	120
133	Role of autophagy in the pathogenesis of inflammatory bowel disease. <b>2017</b> , 23, 1944-1953	81
132	T Helper 17 Cells in Primary Sjögren's Syndrome. <b>2017</b> , 6,	26

131	Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine-Nanobody Complex. <b>2017</b> , 8, 884	21
130	Therapeutic Effects of Methanol Extract from Radix on Imiquimod-Induced Psoriasis. <b>2017</b> , 2017, 7052560	13
129	Salmonella Typhimurium, the major causative agent of foodborne illness inactivated by a phage lysis system provides effective protection against lethal challenge by induction of robust cell-mediated immune responses and activation of dendritic cells. <b>2017</b> , 48, 66	8
128	Emerging targeted therapies for plaque psoriasis - impact of ixekizumab. <b>2017</b> , 10, 133-139	5
127	Oral administration effects of D-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis. <b>2018</b> , 100, 495-500	15
126	Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. <b>2018</b> , 45, 529-539	51
125	Increased risk of psoriasis following scabies infection: A nationwide population-based matched-cohort study. <b>2018</b> , 45, 302-308	6
124	Dual Inhibition of IL-12/IL-23 and Selective Inhibition of IL-23 in Psoriasis. <b>2018</b> , 123-131	3
123	Plasma IL-23 and IL-5 as surrogate markers of lesion metabolic activity in patients with hepatic alveolar echinococcosis. <b>2018</b> , 8, 4417	10
122	When worlds collide: Th17 and Treg cells in cancer and autoimmunity. <b>2018</b> , 15, 458-469	160
121	Tonsil-derived mesenchymal stem cells (T-MSCs) prevent Th17-mediated autoimmune response via regulation of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway. <b>2018</b> , 12, e1022-e1033	38
120	Recurrent angular cheilitis after secukinumab injections. <b>2018</b> , 59, e79-e80	4
119	dbGAPs: A comprehensive database of genes and genetic markers associated with psoriasis and its subtypes. <b>2017</b> , 110, 240-240	2
118	Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials. <b>2018</b> , 32, 68-72	11
117	Sebocytes contribute to skin inflammation by promoting the differentiation of T helper 17 cells. <b>2018</b> , 178, 722-730	31
116	MiR-29a inhibited intestinal epithelial cells autophagy partly by decreasing ATG9A in ulcerative colitis. <b>2018</b> , 29, 652-659	7
115	Sicherheit und unerwünschte Wirkungen der neuesten Biologika. <b>2018</b> , 34, 42-46	
114	Investigational drugs in phase II clinical trials for moderate to severe plaque psoriasis - potential new treatments on the horizon. <b>2018</b> , 27, 931-939	1

113	A Water-Soluble Extract from Ameliorates Psoriasis-Like Skin Inflammation in Mice by Inhibition of Neutrophil Infiltration. <b>2018</b> , 10,	8
112	Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. <b>2018</b> , 8, 49-58	4
111	Application of Photoacoustic Methods and Confocal Microscopy for Monitoring of Therapeutic Response in Plaque Psoriasis. <b>2018</b> , 31, 308-315	7
110	The Pathophysiological Mechanisms and the Quest for Biomarkers in Psoriasis, a Stress-Related Skin Disease. <b>2018</b> , 2018, 5823684	26
109	Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review. <b>2018</b> , 18, 821-827	16
108	Targeting IL-23 in psoriasis: current perspectives. <b>2018</b> , 8, 1-5	31
107	The Gut Microbiome as a Major Regulator of the Gut-Skin Axis. <b>2018</b> , 9, 1459	181
106	miR-340 Alleviates Psoriasis in Mice through Direct Targeting of IL-17A. <b>2018</b> , 201, 1412-1420	12
105	Local production of prolactin in lesions may play a pathogenic role in psoriatic patients and imiquimod-induced psoriasis-like mouse model. <b>2018</b> , 27, 1245-1253	5
104	Understanding the prospective of nano-formulations towards the treatment of psoriasis. <b>2018</b> , 107, 447-463	58
103	The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. <b>2018</b> , 55, 379-390	228
102	Anti IL-17 in psoriasis. <b>2019</b> , 15, 1185-1194	26
101	Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy. <b>2019</b> , 10, 20406223198656587	
100	Tildrakizumab in the treatment of psoriasis - literature review. <b>2019</b> , 57, 234-238	9
99	Tildrakizumab for Moderate-to-Severe Chronic Plaque Psoriasis: a Review of the Literature. <b>2019</b> , 8, 6-13	
98	Characterization of psoriasiform dermatitis induced by systemic injection of interleukin-23 minicircles in mice. <b>2019</b> , 46, 482-497	7
97	IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy. <b>2019</b> , 7, 860-865	40
96	Hepatic serum amyloid A1 upregulates interleukin-17 (IL-17) in $\Gamma$ cells through Toll-like receptor 2 and is associated with psoriatic symptoms in transgenic mice. <b>2019</b> , 89, e12764	6

95	Insights Into the Pathogenesis of Sweet's Syndrome. <b>2019</b> , 10, 414	39
94	Medical Management of Chronic Plaque Psoriasis in the Modern Age. <b>2019</b> ,	
93	Stat3 activation in epidermal keratinocytes induces Langerhans cell activation to form an essential circuit for psoriasis via IL-23 production. <b>2019</b> , 93, 82-91	14
92	Targets of monoclonal antibodies for immunological diseases. <b>2019</b> , 42, 293-304	3
91	Anti-IL17 therapies for psoriasis. <b>2019</b> , 19, 45-54	40
90	A MODEL OF THE OPTIMAL IMMUNOTHERAPY OF PSORIASIS BY INTRODUCING IL-10 AND IL-22 INHIBITORS. <b>2020</b> , 28, 609-639	5
89	A Neutrophil-Driven Inflammatory Signature Characterizes the Blood Transcriptome Fingerprint of Psoriasis. <b>2020</b> , 11, 587946	14
88	Uncovering the mechanism of Jueyin granules in the treatment of psoriasis using network pharmacology. <b>2020</b> , 262, 113214	6
87	Role of Innate Immune Cells in Psoriasis. <b>2020</b> , 21,	18
86	NB-UVB irradiation attenuates inflammatory response in psoriasis. <b>2020</b> , 33, e13626	6
85	Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review. <b>2020</b> , 33, e13800	4
84	Interleukin-23 pathway at the enthesis: The emerging story of enthesitis in spondyloarthritis. <b>2020</b> , 294, 27-47	32
83	Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis. <b>2020</b> , 140, 1546-1555.e4	21
82	Trends in nanotechnology-based delivery systems for dermal targeting of drugs: an enticing approach to offset psoriasis. <b>2020</b> , 17, 817-838	18
81	The Brain-Skin Connection and the Pathogenesis of Psoriasis: A Review with a Focus on the Serotonergic System. <b>2020</b> , 9,	11
80	Aged Mice Exhibit Severe Exacerbations of Dry Eye Disease with an Amplified Memory Th17 Cell Response. <b>2020</b> , 190, 1474-1482	11
79	Interleukin 12/23 Inhibitors. <b>2021</b> , 302-311.e2	
78	Interleukin 23 Inhibitors. <b>2021</b> , 321-329.e2	

77	Loss of keratinocyte Mcpip1 abruptly activates the IL-23/Th17 and Stat3 pathways in skin inflammation. <b>2021</b> , 1868, 118866	2
76	Chinese herbal medicine SS-1 inhibits T cell activation and abrogates T responses in Sjögren's syndrome. <b>2021</b> , 120, 651-659	5
75	The attentive focus on T cell-mediated autoimmune pathogenesis of psoriasis, lichen planus and vitiligo. <b>2021</b> , 93, e13000	8
74	Suppression of neuropeptide by botulinum toxin improves imiquimod-induced psoriasis-like dermatitis via the regulation of neuroimmune system. <b>2021</b> , 101, 58-68	5
73	Cytokines in psoriasis. <b>2021</b> , 100, 171-204	3
72	Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview. <b>2021</b> , 12, 637829	23
71	Small molecule allosteric inhibitors of ROR $\beta$ block Th17-dependent inflammation and associated gene expression in vivo.	
70	Role of IL-23 neutralization in psoriasis – insights from a mechanistic PK/PD model and meta-analysis of clinical data.	
69	Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study. <b>2021</b> , 3, e204-e213	5
68	Advances in the Application of Natural Products and the Novel Drug Delivery Systems for Psoriasis. <b>2021</b> , 12, 644952	6
67	Identification of a Long Noncoding RNA as Key Regulator of IL-17 Signaling through the SRSF10-IRF1-Act1 Axis in Autoimmune Diseases. <b>2021</b> , 206, 2353-2365	6
66	Hyperforin Ameliorates Imiquimod-Induced Psoriasis-Like Murine Skin Inflammation by Modulating IL-17A-Producing $\gamma$ Cells. <b>2021</b> , 12, 635076	1
65	Supplemental <i>Leuconostoc mesenteroides</i> strain NTM048 attenuates imiquimod-induced psoriasis in mice. <b>2021</b> , 131, 3043-3055	3
64	Single-cell analysis of human skin identifies CD14 <sup>+</sup> type 3 dendritic cells co-producing IL1 $\beta$ and IL23A in psoriasis. <b>2021</b> , 218,	16
63	State-of-the-Art Review of Pregnancy-Related Psoriasis. <b>2021</b> , 57,	1
62	Anti-psoriatic and anti-inflammatory effects of <i>Kaempferia parviflora</i> in keratinocytes and macrophage cells. <b>2021</b> , 143, 112229	2
61	Deciphering the mechanism of Fang-Ji-Di-Huang-Decoction in ameliorating psoriasis-like skin inflammation via the inhibition of IL-23/Th17 cell axis. <b>2021</b> , 281, 114571	4
60	Overexpression of hepatic serum amyloid A1 in mice increases IL-17-producing innate immune cells and decreases bone density. <b>2021</b> , 296, 100595	2

59	Construction of an inactivated typhoid vaccine candidate expressing heat-labile enterotoxin B subunit and evaluation of its immunogenicity in a murine model. <b>2017</b> , 66, 1235-1243	7
58	Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study. <b>2021</b> , 48, 807-817	1
57	Aberrant Circulating Th17 Cells in Patients with B-Cell Non-Hodgkin's Lymphoma. <b>2016</b> , 11, e0148044	18
56	Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF- $\alpha$ . <b>2016</b> , 11, e0167437	8
55	Cellular and Molecular Links between Autoimmunity and Lipid Metabolism. <b>2019</b> , 42, 747-754	20
54	Treatment of Psoriasis: A Comprehensive Review of Entire Therapies. <b>2020</b> , 15, 82-104	13
53	The role of gut microbiome in the pathogenesis of psoriasis and the therapeutic effects of probiotics. <b>2019</b> , 8, 3496-3503	23
52	Patients with psoriasis have a higher risk of schizophrenia: A systematic review and meta-analysis of observational studies. <b>2019</b> , 65, 141-145	6
51	Atherogenesis in Psoriasis: Evaluation of the Serum Activities of Non-high-density Lipoprotein Cholesterol and Other Lipids Among Newly Diagnosed Psoriasis Patients. <b>2019</b> , 11, e4203	1
50	Psoriasis. <b>2010</b> , 267-285	
49	Research Pipeline I: Topical Therapies. <b>2014</b> , 217-225	
48	Effect of Narrow Band Ultraviolet B Therapy on Serum Levels of Interleukin22 in Egyptian Patients with Psoriasis. <b>2015</b> , 8, 1-7	
47	Ixekizumab. <b>2016</b> , 153-162	
46	Biologic Therapies for Psoriasis. <b>2017</b> , 757-765	
45	Serum Omentin-1 in Psoriasis. <b>2018</b> , 63, 85-87	0
44	Association between VNN1 gene polymorphism and the risk for psoriasis. <b>2018</b> , 15, 106-110	
43	IL-8 and IL-23 Levels in Peripheral Blood Mononuclear Cells of Patients with Cutaneous Leishmaniasis Caused by Leishmania major: A Case-Control Study. <b>2019</b> , 21,	
42	Choice of first-line genetically engineered biological drugs for moderate and severe psoriasis in patients with comorbid pathology. <b>2020</b> , 18-22	



41	A neutrophil-driven inflammatory signature characterizes the blood cell transcriptome fingerprints of Psoriasis and Kawasaki Disease.	2
40	Improving effect of psoriasis dermatitis by yakuchinone A in the TNF- $\beta$ -stimulated HaCaT cells. <b>2020</b> , 63, 95-101	
39	Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis. <b>2020</b> , 14, 165-170	1
38	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting. <b>2014</b> , 7, S5-S22	
37	Diagnosing Psoriatic Arthritis from the Dermatologist's View. <b>2013</b> , 3, 85-90	
36	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. <b>2016</b> , 9, S5-S29	2
35	Inside-out and outside-in organotypic normal human skin culture: JAK-STAT pathway is activated after pro-inflammatory psoriatic cytokine exposure. <b>2021</b> , 74, 101675	3
34	Association analysis of MALAT1 polymorphisms and risk of psoriasis among Iranian patients. <b>2021</b> ,	1
33	Small molecule allosteric inhibitors of ROR $\gamma$ block Th17-dependent inflammation and associated gene expression in vivo. <b>2021</b> , 16, e0248034	0
32	TNFR2 depletion reduces psoriatic inflammation in mice via downregulating specific dendritic cell populations in lymph nodes and inhibiting IL-23/IL-17 pathways.. <b>2022</b> ,	0
31	Immune mechanisms of psoriasis. New strategies of biotherapy. <b>2010</b> , 86, 35-47	11
30	Autoimmune Pemphigus: Latest Advances and Emerging Therapies.. <b>2021</b> , 8, 808536	1
29	Developing Novel Molecular Targeted Therapeutics for Topical Treatment of Psoriasis.	
28	Co-encapsulation of Metformin and Ginger into the liposomes: In Vitro Characterization and In vivo Anti- Psoriasis Evaluation.. <b>2022</b> , 1-34	
27	Asiatic acid exerts an anti-psoriatic effect in the imiquimod-induced psoriasis model in mice.. <b>2022</b> , 1-6	1
26	Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report.. <b>2022</b> , 16, 1-5	0
25	Mononuclear subsets and cytokine profile of venous and capillary blood in patients with psoriasis and healthy people. <b>2021</b> , 23, 1333-1346	0
24	An Analysis of , , , and Expression and Their Correlation with Clinical Course in Patients with Psoriasis.. <b>2021</b> , 10,	1

23	Anti-Psoriatic Effects and IL-22 Targeting Mechanism of Indirubin by Suppressing Keratinocyte Inflammation and Proliferation. <b>2021</b> , 11, 11599	
22	Effective topical treatments of innovative NNO-tridentate vanadium (IV) complexes-mediated photodynamic therapy in psoriasis-like mice model.	0
21	Value of PASI90 Versus Merit-Based Incentive Payment System Efficacy Measures. 247553032210826	
20	Image_1.jpeg. <b>2020</b> ,	
19	Table_1.xlsx. <b>2020</b> ,	
18	Skin Inflammation Modulation via TNF- $\alpha$ /IL-17, and IL-12 Family Inhibitors Therapy and Cancer Control in Patients with Psoriasis.. <b>2022</b> , 23,	
17	Interleukin 12/23 inhibitors. <b>2013</b> , 319-332.e2	
16	Two Main Cellular Components in Rheumatoid Arthritis: Communication Between T Cells and Fibroblast-Like Synoviocytes in the Joint Synovium. 13,	1
15	Efficacy and Safety of Mirikizumab in Psoriasis: Results from a 52-Week , Double-Blinded , Placebo-Controlled , Randomised Withdrawal, Phase III Trial ( OASIS -1).	1
14	Erythrodermic psoriasis improved by tildrakzumab: a case report.	
13	The Role of KEAP1-NRF2 System in Atopic Dermatitis and Psoriasis. <b>2022</b> , 11, 1397	1
12	Successful treatment of severe pityriasis rubra pilaris with secukinumab in a 3-year-old boy.	0
11	Contribution of the Environment, Epigenetic Mechanisms and Non-Coding RNAs in Psoriasis. <b>2022</b> , 10, 1934	1
10	An Update on Photodynamic Therapy of Psoriasis: Current Strategies and Nanotechnology as a Future Perspective. <b>2022</b> , 23, 9845	1
9	Psoriasis and medical ramifications: A comprehensive analysis based on observational meta-analyses. 9,	0
8	Formulation of secretome derived from mesenchymal stem cells for inflammatory skin diseases.	0
7	IL-23 Inhibition in Psoriasis: Changing the Present, Shaping the Future. 62-70	0
6	IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability. 112-123	0

- 5 Clinical characteristics, management, and quality of life of psoriasis patients with coexistent lupus erythematosus: Data from the Malaysian Psoriasis Registry. ○
- 4 Diosmin nanocrystals alleviate Imiquimod induced psoriasis in rats via modulating TLR7,8/NF-**B**/micro RNA-31, AKT/mTOR/P70S6K milieu and Tregs / Th17 balance. ○
- 3 Fufang Shengdi mixture alleviates psoriasis-like skin inflammation via promoting Annexin-A proteins expression. **2023**, 312, 116329 ○
- 2 Centipeda minima Extract Inhibits Inflammation and Cell Proliferation by Regulating JAK/STAT Signaling in Macrophages and Keratinocytes. **2023**, 28, 1723 ○
- 1 Diosmin nanocrystal gel alleviates imiquimod-induced psoriasis in rats via modulating TLR7,8/NF-**B**/micro RNA-31, AKT/mTOR/P70S6K milieu, and Tregs/Th17 balance. ○